S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.93 (-4.98%)
AAPL   140.65 (-5.76%)
MSFT   254.13 (-4.76%)
FB   192.54 (-4.97%)
GOOGL   2,242.68 (-3.73%)
AMZN   2,139.15 (-7.29%)
TSLA   708.27 (-7.00%)
NVDA   169.86 (-6.55%)
BABA   87.41 (-4.98%)
NIO   15.80 (-4.99%)
AMD   96.59 (-5.74%)
CGC   5.59 (-5.09%)
MU   71.28 (-4.30%)
T   20.17 (-1.94%)
GE   75.06 (-1.75%)
F   12.75 (-5.76%)
DIS   104.21 (-4.08%)
AMC   12.70 (-1.55%)
PFE   50.34 (-1.95%)
PYPL   77.21 (-3.18%)
NFLX   177.25 (-6.98%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.93 (-4.98%)
AAPL   140.65 (-5.76%)
MSFT   254.13 (-4.76%)
FB   192.54 (-4.97%)
GOOGL   2,242.68 (-3.73%)
AMZN   2,139.15 (-7.29%)
TSLA   708.27 (-7.00%)
NVDA   169.86 (-6.55%)
BABA   87.41 (-4.98%)
NIO   15.80 (-4.99%)
AMD   96.59 (-5.74%)
CGC   5.59 (-5.09%)
MU   71.28 (-4.30%)
T   20.17 (-1.94%)
GE   75.06 (-1.75%)
F   12.75 (-5.76%)
DIS   104.21 (-4.08%)
AMC   12.70 (-1.55%)
PFE   50.34 (-1.95%)
PYPL   77.21 (-3.18%)
NFLX   177.25 (-6.98%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.93 (-4.98%)
AAPL   140.65 (-5.76%)
MSFT   254.13 (-4.76%)
FB   192.54 (-4.97%)
GOOGL   2,242.68 (-3.73%)
AMZN   2,139.15 (-7.29%)
TSLA   708.27 (-7.00%)
NVDA   169.86 (-6.55%)
BABA   87.41 (-4.98%)
NIO   15.80 (-4.99%)
AMD   96.59 (-5.74%)
CGC   5.59 (-5.09%)
MU   71.28 (-4.30%)
T   20.17 (-1.94%)
GE   75.06 (-1.75%)
F   12.75 (-5.76%)
DIS   104.21 (-4.08%)
AMC   12.70 (-1.55%)
PFE   50.34 (-1.95%)
PYPL   77.21 (-3.18%)
NFLX   177.25 (-6.98%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.93 (-4.98%)
AAPL   140.65 (-5.76%)
MSFT   254.13 (-4.76%)
FB   192.54 (-4.97%)
GOOGL   2,242.68 (-3.73%)
AMZN   2,139.15 (-7.29%)
TSLA   708.27 (-7.00%)
NVDA   169.86 (-6.55%)
BABA   87.41 (-4.98%)
NIO   15.80 (-4.99%)
AMD   96.59 (-5.74%)
CGC   5.59 (-5.09%)
MU   71.28 (-4.30%)
T   20.17 (-1.94%)
GE   75.06 (-1.75%)
F   12.75 (-5.76%)
DIS   104.21 (-4.08%)
AMC   12.70 (-1.55%)
PFE   50.34 (-1.95%)
PYPL   77.21 (-3.18%)
NFLX   177.25 (-6.98%)
OTCMKTS:ICOTF

iCo Therapeutics (ICOTF) Stock Forecast, Price & News

$0.03
0.00 (0.00%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.03
▼
$0.03
50-Day Range
$0.02
▼
$0.90
52-Week Range
$0.80
▼
$1.82
Volume
N/A
Average Volume
4,760 shs
Market Capitalization
$226.35 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.03
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive ICOTF News and Ratings via Email

Sign-up to receive the latest news and ratings for iCo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

iCo Therapeutics logo

About iCo Therapeutics

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Headlines

December 16, 2021 | finance.yahoo.com
Satellos Bioscience Inc. Announces Scientific Research Agreement with Université de Sherbrooke to Study Rare Muscular Dystrophies
December 15, 2021 | finance.yahoo.com
Satellos Bioscience to Webcast Live at Life Sciences Investor Forum December 16th
December 9, 2021 | finance.yahoo.com
ICOTF: Targeting Stem Cells for Muscular Dystrophy Treatment
December 6, 2021 | finance.yahoo.com
Satellos Bioscience Announces New Board Appointments
November 29, 2021 | finance.yahoo.com
Satellos Bioscience Reports Third Quarter 2021 Financial Results and Operational Highlights
October 27, 2021 | finance.yahoo.com
Satellos Bioscience Inc. Retains BND Projects Inc. for Strategic Investor Relations Services
August 5, 2021 | finance.yahoo.com
iCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.
July 9, 2021 | finance.yahoo.com
iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Approval and Provides Update Regarding Business Combination with Satellos Bioscience Inc.
June 2, 2021 | finanznachrichten.de
iCo Therapeutics Inc.: iCo Therapeutics Announces First Quarter 2021 Financial Results
May 11, 2021 | finance.yahoo.com
iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences Meeting
April 29, 2021 | finance.yahoo.com
iCo Therapeutics Announces 2020 Year End Financial Results and Resignation of Susan Koppy
April 27, 2021 | finance.yahoo.com
iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receipt Private Placement
April 23, 2021 | finance.yahoo.com
iCo Therapeutics Inc. Announces Upsized Subscription Receipt Private Placement
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ICOTF
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.icotherapeutics.com
Phone
(905) 336-6128
Fax
604-602-9699
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
-0.36

Profitability

EPS (Most Recent Fiscal Year)
($0.400010)
Net Income
$-1.11 million
Net Margins
N/A
Pretax Margin
-4,148.78%
Return on Equity
N/A
Return on Assets
-288.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.72
Quick Ratio
0.72

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
9,054,000
Free Float
N/A
Market Cap
$226.35 thousand
Optionable
Not Optionable

Company Calendar

Today
5/18/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













iCo Therapeutics (OTCMKTS:ICOTF) Frequently Asked Questions

Who are iCo Therapeutics' key executives?
iCo Therapeutics' management team includes the following people:
  • Frank Gleeson, President & Chief Executive Officer
  • Warren Whitehead, Chief Financial Officer
  • Michael Rudnicki, Chief Scientific Officer
  • J. Robert Hall, Vice President-Finance & Administration
What is iCo Therapeutics' stock symbol?

iCo Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF."

How do I buy shares of iCo Therapeutics?

Shares of ICOTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iCo Therapeutics' stock price today?

One share of ICOTF stock can currently be purchased for approximately $0.03.

How much money does iCo Therapeutics make?

iCo Therapeutics has a market capitalization of $226.35 thousand. The biotechnology company earns $-1.11 million in net income (profit) each year or ($0.400010) on an earnings per share basis.

What is iCo Therapeutics' official website?

The official website for iCo Therapeutics is www.icotherapeutics.com.

How can I contact iCo Therapeutics?

iCo Therapeutics' mailing address is 777 Hornby Street 6th Floor, Vancouver A1, V6Z 2T3. The biotechnology company can be reached via phone at (905) 336-6128, via email at [email protected], or via fax at 604-602-9699.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.